Skip to main content
PMC home page
Malaria Journal logoLink to Malaria Journal
. 2022 Feb 7;21:37. doi: 10.1186/s12936-022-04049-1

Correction to: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda

Chris Ebong 1,✉, Asadu Sserwanga 1, Jane Frances Namuganga 1, James Kapisi 1, Arthur Mpimbaza 1, Samuel Gonahasa 1, Victor Asua 1, Sam Gudoi 2, Ruth Kigozi 2, James Tibenderana 2, John Bosco Bwanika 2, Agaba Bosco 3, Denis Rubahika 3, Daniel Kyabayinze 3, Jimmy Opigo 3, Damian Rutazana 3, Gloria Sebikaari 4, Kassahun Belay 4, Mame Niang 4, Eric S Halsey 5, Leah F Moriarty 5, Naomi W Lucchi 5, Samaly S Svigel Souza 5, Sam L Nsobya 1,6, Moses R Kamya 1,6, Adoke Yeka 1,6
PMCID: PMC8822855  PMID: 35130919

Correction to: Malaria Journal (2021) 20:484 https://doi.org/10.1186/s12936-021-04021-5

Following publication of the original article [1], it was brought to the publisher’s attention that incorrect details had been provided in the trial registration information of the article.

Where it should read:

  • Trial registration: The trial was also registered with the Pan African Clinical Trial Registry (https://pactr.samrc.ac.za/) with study Trial No. PACTR201811640750761.

It said:

  • Trial registration: The trial was also registered with the ISRCTN registry with study Trial No. PACTR201811640750761.

The original article has been updated accordingly.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Reference

  • 1.Ebong C, Sserwanga A, Namuganga JF, Kapisi J, Mpimbaza A, Gonahasa S, Asua V, Gudoi S, Kigozi R, Tibenderana J, Bwanika JB, Bosco A, Rubahika D, Kyabayinze D, Opigo J, Rutazana D, Sebikaari G, Belay K, Niang M, Halsey ES, Moriarty LF, Lucchi NW, Souza SSS, Nsobya SL, Kamya MR, Yeka A. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. Malar J. 2021;20:484. doi: 10.1186/s12936-021-04021-5. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Malaria Journal are provided here courtesy of BMC

RESOURCES